Senanayake Preenie deS, Drazba Judy, Shadrach Karen, Milsted Amy, Rungger-Brandle Elisabeth, Nishiyama Kazutoshi, Miura Shin-Ichiro, Karnik Sadashiva, Sears Jonathan E, Hollyfield Joe G
Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3301-11. doi: 10.1167/iovs.06-1024.
To quantify and evaluate the distribution of angiotensin II (Ang II) and its receptors in the human retina.
Donor eyes were obtained within 12 hours postmortem and classified as hypertensive or normotensive and diabetic or nondiabetic, based on the donors' medical histories. Ang II in retina and vitreous was quantified by RIA. Ang II receptors were characterized and quantified by competitive membrane-binding assays. Ang II, its heptapeptide metabolite Ang-(1-7), and AT1 and AT2 receptors were localized by immunohistochemistry and confocal imaging.
Levels of Ang II in the retina were significantly higher than in vitreous (P < 0.05). Ang II in the diabetic retina had a higher median compared with that in the nondiabetic retina. Ang II and Ang-(1-7) colocalized in retinal Müller cells. The retina had the highest levels of Ang II receptors that were significantly higher than the optic nerve, retinal pigment epithelium-choroid complex, and ciliary body-iris complex (P < 0.05). AT1 receptors were more abundant than AT2 receptors in the retina. Immunoreactivity for AT1 was detected in Müller cells and on blood vessels. AT2 receptors were localized throughout the Müller cells and nuclei of ganglion cells and neurons in the inner nuclear layer.
In the human retina, identification of Ang II and its bioactive metabolite Ang-(1-7) in Müller cells suggests that these glial cells are able to produce and process Ang II. Ang receptors were localized in the blood vessels and neural cells. Local Ang II signaling may thus allow for autoregulation of neurovascular activity. Such an autonomous system could modulate the onset and severity of retinovascular disease.
定量并评估血管紧张素II(Ang II)及其受体在人视网膜中的分布。
根据供体的病史,在死后12小时内获取供体眼,并将其分为高血压或血压正常以及糖尿病或非糖尿病组。通过放射免疫分析法(RIA)对视网膜和玻璃体中的Ang II进行定量。通过竞争性膜结合试验对Ang II受体进行表征和定量。通过免疫组织化学和共聚焦成像对Ang II及其七肽代谢产物Ang-(1-7)以及AT1和AT2受体进行定位。
视网膜中Ang II的水平显著高于玻璃体(P < 0.05)。与非糖尿病视网膜相比,糖尿病视网膜中Ang II的中位数更高。Ang II和Ang-(1-7)在视网膜Müller细胞中共定位。视网膜中Ang II受体的水平最高,显著高于视神经、视网膜色素上皮-脉络膜复合体和睫状体-虹膜复合体(P < 0.05)。视网膜中AT1受体比AT2受体更丰富。在Müller细胞和血管上检测到AT1的免疫反应性。AT2受体定位于整个Müller细胞以及神经节细胞和内核层神经元的细胞核中。
在人视网膜中,在Müller细胞中鉴定出Ang II及其生物活性代谢产物Ang-(1-7)表明这些神经胶质细胞能够产生和加工Ang II。Ang受体定位于血管和神经细胞中。局部Ang II信号传导可能因此允许神经血管活动的自动调节。这样一个自主系统可以调节视网膜血管疾病的发生和严重程度。